Cardiovascular diseases are the most prevalent class of diseases in the world; more individuals die from heart diseases than any other illness. Despite current and past efforts, diagnosis and treatment options are limited. The underlying molecular mechanisms that lead to the onset and progression of detrimental phenotypes in the heart remain largely elusive. The major goals of the HUPO Cardiovascular Initiative include the development and utilization of cutting-edge proteomics technologies and beyond to map the dynamic cardiac and vascular proteomes, elucidate cardiovascular disease mechanisms, identify candidate therapeutic targets, and provide clinically useful diagnosis as well as risk prediction. Emphasis is given to promoting the development and adoption of quantitative protein assays targeting relevant cardiovascular proteins, elucidating the complete cardiovascular proteome at single cell and proteoform resolution, and application of large-scale screening towards clinical diagnostics and prognosis of heart diseases.

Current lines of work:

• Continual development of computational algorithms to prioritize popular proteins for expedited quantitative proteomics assay development.
• Quantitation of cardiovascular proteins using integrated antibody and targeted MRM approaches.
• Characterization of proteins relevant to the onset, progression and reversal of cardiovascular diseases including cardiac hypertrophy, aortic aneurysm, vasculopathies, and others.
• Deciphering the impact of posttranslational modifications (e.g., citrullination, phosphorylation, etc.) in signalling and protein regulation under cardiovascular physiology and pathophysiology.
• Systematically derived popular and relevant proteins from >20,000 terms from 4 ontologies of human diseases (DOID, HPO, PW, BTO).
• Utilized a data-driven approach to create a human protein diseasome.
• Derived a comprehensive proteomic architecture of human coronary and aortic atherosclerosis.
• Provided insights into the cysteine oxidative posttranslational modification proteome during cardiac hypertrophy.

Links:

Papers:

Parker SJ, Venkatraman V, Van Eyk JE. Effect of peptide assay library size and composition in targeted data-independent acquisition-MS analyses. Proteomics. 2016 Aug;16(15-16):2221-37. doi: 10.1002/pmic.201600007.

Lam MP, Venkatraman V, Cao Q, Wang D, Dincer TU, Lau E, Su AI, Xing Y, Ge J, Ping P, Van Eyk JE. Prioritizing Proteomics Assay Development for Clinical Translation. J Am Coll Cardiol. 2015 Jul 14;66(2):202-4.

Lam MP, Venkatraman V, Xing Y, Lau E, Cao Q, Ng DC, Su AI, Ge J, Van Eyk JE, Ping P. Data-Driven Approach To Determine Popular Proteins for Targeted Proteomics Translation of Six Organ Systems. J Proteome Res. 2016 Jul 19. [Epub ahead of print]

Semba RD, Lam M, Sun K, Zhang P, Schaumberg DA, Ferrucci L, Ping P, Van Eyk JE. Priorities and trends in the study of proteins in eye research, 1924-2014. Proteomics Clin Appl. 2015 Dec;9(11-12):1105-22. doi: 10.1002/prca.201500006.

Fert-Bober J, Giles JT, Holewinski RJ, Kirk JA, Uhrigshardt H, Crowgey EL, Andrade F, Bingham CO 3rd, Park JK, Halushka MK, Kass DA, Bathon JM, Van Eyk JE. Citrullination of myofilament proteins in heart failure. Cardiovasc Res. 2015 Nov 1;108(2):232-42.

For more information or participation opportunities please contact office(at)hupo.org.